Literature DB >> 3622599

Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis.

J Evers, R Bonn, A Boertz, W Cawello, V Luckow, M Fey, F Aboudan, H A Dickmans.   

Abstract

The pharmacokinetics of isosorbide-5-nitrate (IS-5-N) was studied in ten patients on haemodialysis (HD) after a single oral dose of 20 mg IS-5-N, and in six patients on continuous ambulatory peritoneal dialysis (CAPD) after repeated oral doses of 3 X 20 mg IS-5-N. There was significant removal of IS-5-N from blood during HD; Cmax decreased by about 20%, AUC(0-8 h) by 30% and t1/2 by about 20% from 4.3 to 3.4 h, and plasma clearance was increased by 81 ml/min. No important loss of IS-5-N was observed in patients on CAPD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3622599     DOI: 10.1007/bf00637678

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  [Pharmacokinetics of isosorbide-5-mononitrate in patients with advanced renal failure].

Authors:  W Kösters; P Klotschkoff; U Abshagen
Journal:  Med Welt       Date:  1981-04-07

2.  First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man.

Authors:  U Abshagen; S Spörl-Radun
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

3.  Isosorbide 5-mononitrate kinetics.

Authors:  R M Major; T Taylor; L F Chasseaud; A Darragh; R F Lambe
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

4.  Pharmacokinetics of isosorbide-5-nitrate in renal failure.

Authors:  J Evers; B Krakamp; W Klimkait; H A Dickmans; J Maddock; V Luckow; W Cawello; M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results.

Authors:  H C Steudel; M Volkenandt; A T Steudel
Journal:  Z Kardiol       Date:  1983

6.  Fate of isosorbide dinitrate and mononitrates in patients with renal failure.

Authors:  M G Bogaert; M T Rosseel; J Boelaert; R Daneels
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 7.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

8.  Metabolic fact of 14C-isosorbide 5-mononitrate in humans.

Authors:  S G Wood; B A John; L F Chasseaud; R M Major; M E Forrest; R Bonn; A Darragh; R F Lambe
Journal:  Arzneimittelforschung       Date:  1984

9.  Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.

Authors:  H Laufen; M Aumann; M Leitold
Journal:  Arzneimittelforschung       Date:  1983

10.  Isosorbide 5-mononitrate pharmacokinetics in humans.

Authors:  T Taylor; L F Chasseaud; R Major; E Doyle; A Darragh
Journal:  Biopharm Drug Dispos       Date:  1981 Jul-Sep       Impact factor: 1.627

View more
  2 in total

Review 1.  Clinical pharmacokinetics of nitrates.

Authors:  M G Bogaert
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 2.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.